Seunghyeok Choi,Hanbi Lee,Hye-Eun Yoon,Silvia Park,Byung Ha Chung
{"title":"严重再生障碍性贫血患者的肾移植:4例患者耐受或血液恢复的病例系列。","authors":"Seunghyeok Choi,Hanbi Lee,Hye-Eun Yoon,Silvia Park,Byung Ha Chung","doi":"10.1016/j.ajt.2025.09.002","DOIUrl":null,"url":null,"abstract":"Severe aplastic anemia (SAA) is a bone marrow failure syndrome characterized by pancytopenia and hypocellular marrow. When accompanied by end-stage kidney disease (ESKD), it presents a significant therapeutic challenge. While allogeneic hematopoietic stem cell transplantation (HSCT) is the definitive treatment for SAA and kidney transplantation (KT) is the optimal therapy for ESKD, the ideal sequencing and strategy for performing both procedures remain unclear. We report successful outcomes in four patients with concurrent SAA and ESKD managed using a KT-first approach. All patients demonstrated immediate graft function without surgical complications, and no episodes of acute rejection were observed within the first year post-transplant. Two patients subsequently underwent HSCT from the same donor used for KT, approximately three months after KT. Both achieved hematologic remission and were eventually able to discontinue all immunosuppressive medications. Remarkably, the other two patients experienced spontaneous hematologic improvement and no longer required HSCT. These findings suggest that the KT-first approach is both feasible and safe, serving not only as a bridge to curative HSCT but also, in select cases, as a potential standalone therapy for SAA. This case series provides preliminary evidence supporting the role of the KT-first strategy in patients with coexisting SAA and ESKD.","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"51 1","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Kidney Transplantation in Patients with Severe Aplastic Anemia: A Case Series of Four Patients Bridging to Tolerance or Hematologic Recovery.\",\"authors\":\"Seunghyeok Choi,Hanbi Lee,Hye-Eun Yoon,Silvia Park,Byung Ha Chung\",\"doi\":\"10.1016/j.ajt.2025.09.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Severe aplastic anemia (SAA) is a bone marrow failure syndrome characterized by pancytopenia and hypocellular marrow. When accompanied by end-stage kidney disease (ESKD), it presents a significant therapeutic challenge. While allogeneic hematopoietic stem cell transplantation (HSCT) is the definitive treatment for SAA and kidney transplantation (KT) is the optimal therapy for ESKD, the ideal sequencing and strategy for performing both procedures remain unclear. We report successful outcomes in four patients with concurrent SAA and ESKD managed using a KT-first approach. All patients demonstrated immediate graft function without surgical complications, and no episodes of acute rejection were observed within the first year post-transplant. Two patients subsequently underwent HSCT from the same donor used for KT, approximately three months after KT. Both achieved hematologic remission and were eventually able to discontinue all immunosuppressive medications. Remarkably, the other two patients experienced spontaneous hematologic improvement and no longer required HSCT. These findings suggest that the KT-first approach is both feasible and safe, serving not only as a bridge to curative HSCT but also, in select cases, as a potential standalone therapy for SAA. This case series provides preliminary evidence supporting the role of the KT-first strategy in patients with coexisting SAA and ESKD.\",\"PeriodicalId\":123,\"journal\":{\"name\":\"American Journal of Transplantation\",\"volume\":\"51 1\",\"pages\":\"\"},\"PeriodicalIF\":8.2000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ajt.2025.09.002\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ajt.2025.09.002","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
Kidney Transplantation in Patients with Severe Aplastic Anemia: A Case Series of Four Patients Bridging to Tolerance or Hematologic Recovery.
Severe aplastic anemia (SAA) is a bone marrow failure syndrome characterized by pancytopenia and hypocellular marrow. When accompanied by end-stage kidney disease (ESKD), it presents a significant therapeutic challenge. While allogeneic hematopoietic stem cell transplantation (HSCT) is the definitive treatment for SAA and kidney transplantation (KT) is the optimal therapy for ESKD, the ideal sequencing and strategy for performing both procedures remain unclear. We report successful outcomes in four patients with concurrent SAA and ESKD managed using a KT-first approach. All patients demonstrated immediate graft function without surgical complications, and no episodes of acute rejection were observed within the first year post-transplant. Two patients subsequently underwent HSCT from the same donor used for KT, approximately three months after KT. Both achieved hematologic remission and were eventually able to discontinue all immunosuppressive medications. Remarkably, the other two patients experienced spontaneous hematologic improvement and no longer required HSCT. These findings suggest that the KT-first approach is both feasible and safe, serving not only as a bridge to curative HSCT but also, in select cases, as a potential standalone therapy for SAA. This case series provides preliminary evidence supporting the role of the KT-first strategy in patients with coexisting SAA and ESKD.
期刊介绍:
The American Journal of Transplantation is a leading journal in the field of transplantation. It serves as a forum for debate and reassessment, an agent of change, and a major platform for promoting understanding, improving results, and advancing science. Published monthly, it provides an essential resource for researchers and clinicians worldwide.
The journal publishes original articles, case reports, invited reviews, letters to the editor, critical reviews, news features, consensus documents, and guidelines over 12 issues a year. It covers all major subject areas in transplantation, including thoracic (heart, lung), abdominal (kidney, liver, pancreas, islets), tissue and stem cell transplantation, organ and tissue donation and preservation, tissue injury, repair, inflammation, and aging, histocompatibility, drugs and pharmacology, graft survival, and prevention of graft dysfunction and failure. It also explores ethical and social issues in the field.